Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
John Dipersio
Washington University, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Magenta Therapeutics
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The Conflicts of Interest Review Committee (CIRC) determined Dr. Dipersio’s personal financial relationship with Magenta Therapeutics, related to the above referenced research, creates a financial conflict of interest due to the following reasons:
• A focus of Magenta Therapeutics, an entity with which Dr. Dipersio owns equity, is to commercialize IP co-invented by Dr. Dipersio entitled; “ELA for Combination of Groβ or truncated Groβ (Groβt) plus a VLA-4 small molecule inhibitor (CWHM-823 and derivatives thereof ) for hematopoietic stem cell mobilization and leukemia chemosensitization”, and the IP is being evaluated in the research listed above.
• The determination to execute a license by Magenta Therapeutics for the IP may be impacted by the outcomes of the research
• Dr. Dipersio’s role as PI, involved in study design, data collection, analysis, and review, reporting the results, as mentor and supervisor of individuals involved with the research, and oversight of the research., could directly affect the study
While it was determined a financial conflict of interest exists, the CIRC concluded sufficient mechanisms exist to ensure the objectivity and integrity of the research, based on the following reasons:
• Dr. Dipersio is uniquely qualified by virtue of his experience and expertise, and the research could not be conducted as efficiently or effectively without his involvement.
• There is currently no active license for the IP being evaluated.
• Additionally, a management plan has been developed to mitigate his financial conflict of interest.
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies
PROJECT NARRATIVE Allogeneic hematopoietic stem cell transplant (HSCT) is the only curative therapy for many patients with hematologic malignancies and marrow failure states. We will overcome many of the major limitations to successful HSCT by designing and testing in clinical trials our basic science observations which have identified optimal methods of mobilizing stem cells for HSCT and for sensitizing acute myelogenous leukemia (AML) to chemotherapy, by developing and implementing novel methods to prevent graft-versus-host disease (GvHD), the major complication of allogeneic HSCT, and by developing novel immunotherapies for AML and T-ALL.
Filed on November 15, 2017.
Tell us what you know about John Dipersio's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
John Dipersio filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| John Dipersio | Washington University | Conflict of Interest | Magenta Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.